Stem Cell Authority Ltd
Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. It specializes in the collection and cryogenic preservation of the hematopoietic stem cells from the umbilical cord blood; and the Miracle Mesenchymal stem cells from the Wharton's jelly inside the umbilical cord of a newborn child. The company's technology enables birt… Read more
Stem Cell Authority Ltd (SCAL) - Net Assets
Latest net assets as of May 2007: $454.48K USD
Based on the latest financial reports, Stem Cell Authority Ltd (SCAL) has net assets worth $454.48K USD as of May 2007.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.72 Million) and total liabilities ($2.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $454.48K |
| % of Total Assets | 16.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Stem Cell Authority Ltd - Net Assets Trend (2001–2009)
This chart illustrates how Stem Cell Authority Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Stem Cell Authority Ltd (2001–2009)
The table below shows the annual net assets of Stem Cell Authority Ltd from 2001 to 2009.
| Year | Net Assets | Change |
|---|---|---|
| 2009-08-31 | $-92.12K | +95.21% |
| 2008-08-31 | $-1.92 Million | -135.08% |
| 2007-08-31 | $-818.55K | +43.96% |
| 2006-08-31 | $-1.46 Million | -1714.41% |
| 2002-08-31 | $-80.51K | -105.38% |
| 2001-08-31 | $-39.20K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Stem Cell Authority Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 50306600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2009)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $453.14K | % |
| Total Equity | $-92.12K | 100.00% |
Stem Cell Authority Ltd Competitors by Market Cap
The table below lists competitors of Stem Cell Authority Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KS International Holdings Corporation
PINK:KSIH
|
$1.84 |
|
MobiVentures Inc
PINK:MBLV
|
$1.85 |
|
Idarado Mining Company
PINK:IDAM
|
$1.85 |
|
Fidelity Holding Corp
PINK:FDHC
|
$1.85 |
|
Coil Tubing Technology Inc
PINK:CTBG
|
$1.84 |
|
Sortis Holdings Inc
PINK:SOHI
|
$1.84 |
|
Oct 88 Res Inc
PINK:OCTX
|
$1.84 |
|
RONN Inc.
PINK:RONN
|
$1.84 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Stem Cell Authority Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2008 to 2009, total equity changed from -1,924,251 to -92,121, a change of 1,832,130.
- Net income of 1,832,133 contributed positively to equity growth.
- Other factors decreased equity by 3.
Equity Change Factors (2008 to 2009)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.83 Million | +1988.83% |
| Other Changes | $-3.00 | -0.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Stem Cell Authority Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-08-31 | $-0.01 | $0.00 | x |
| 2002-08-31 | $-0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Stem Cell Authority Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 55.06%
- • Asset Turnover: 0.83x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-38.28K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-33.26K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-518.08K |
| 2007 | 0.00% | 84.82% | 1.48x | 0.00x | $1.04 Million |
| 2008 | 0.00% | -4643.98% | 0.04x | 0.00x | $-1.19 Million |
| 2009 | 0.00% | 55.06% | 0.83x | 0.00x | $1.84 Million |
Industry Comparison
This section compares Stem Cell Authority Ltd's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $250,407,165
- Average return on equity (ROE) among peers: -38.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Stem Cell Authority Ltd (SCAL) | $454.48K | 0.00% | 4.99x | $1.84 |
| Addus HomeCare Corporation (ADUS) | $113.86 Million | 16.82% | 0.44x | $1.75 Billion |
| agilon health Inc (AGL) | $126.73 Million | -319.84% | 9.03x | $166.17 Million |
| Airsculpt Technologies Inc (AIRS) | $123.68 Million | 6.13% | 0.45x | $16.62 Million |
| Amedisys Inc (AMED) | $454.23 Million | -18.40% | 0.61x | $3.26 Billion |
| AMN Healthcare Services Inc (AMN) | $347.86 Million | 23.54% | 1.53x | $624.22 Million |
| American Shared Hospital Service (AMS) | $20.85 Million | 8.48% | 1.33x | $7.93 Million |
| American Oncology Network Inc. (AONC) | $226.04 Million | -0.05% | 0.10x | $112.23 Million |
| Ardent Health Partners, Inc. (ARDT) | $1.08 Billion | 4.65% | 3.71x | $225.22 Million |
| Arem Pacific Corporation (ARPC) | $-45.09K | 0.00% | 0.00x | $246.12K |
| Astrana Health Inc (ASTH) | $8.55 Million | -109.27% | 1.29x | $1.08 Billion |